Turner Syndrome Market Report 2026

The turner syndrome market size has grown strongly in recent years. It will grow from $2.54 billion in 2025 to $2.73 billion in 2026 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to increased awareness of genetic disorders, availability of recombinant growth hormones, expansion of pediatric endocrinology services, improved diagnostic karyotyping techniques, rising patient advocacy initiatives.

The turner syndrome market size is expected to see strong growth in the next few years. It will grow to $3.63 billion in 2030 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to advancements in genetic screening technologies, growing adoption of personalized hormone therapies, expansion of home-based care models, increasing investment in rare disease research, improved long-term patient outcomes. Major trends in the forecast period include increasing focus on early genetic diagnosis, rising adoption of growth hormone therapies, growing emphasis on lifelong disease management, expansion of multidisciplinary care models, improved patient monitoring programs.

The expanding female population is expected to drive the growth of the Turner syndrome market in the coming years. The female population represents the total number of women and girls living within a specific region or globally at a given point in time. Growth in the female population is largely attributed to higher life expectancy among females, supported by improvements in healthcare and ongoing demographic transitions. The Turner syndrome market supports this population by providing therapies such as growth hormone treatment, estrogen replacement, and multidisciplinary care approaches that promote physical development, reproductive health, and long-term overall well-being. For example, in March 2024, the U.S. Census Bureau reported that the United States had approximately 0.168 billion females as of July 2022. Additionally, Statistics Canada reported that in 2023, the number of females aged 15-64 increased to 0.01304 billion, up from 0.01296 billion in 2022. Consequently, the rising female population is contributing to the growth of the Turner syndrome market.

Key companies operating in the Turner syndrome market are emphasizing clinical trials to develop innovative therapies, such as pediatric growth hormone medications, aimed at effectively stimulating growth, improving height outcomes, and supporting overall development in children with growth hormone deficiencies or growth-related conditions. Pediatric growth hormone therapies are synthetic or recombinant hormone treatments used to promote growth and development in children with growth hormone deficiency (GHD) and other disorders affecting stature. For instance, in December 2024, Ascendis Pharma A/S, a Denmark-based biopharmaceutical company, announced positive Phase 2 results from the New InsiGHTS trial of TransCon hGH (lonapegsomatropin) in children with Turner syndrome. The study enrolled 49 prepubertal children aged 1 to 10 years with Turner syndrome, and TransCon hGH demonstrated enhanced growth across all three starting dose cohorts, performing comparably to daily somatropin. These findings support the potential expansion of TransCon hGH into the Turner syndrome market, with efficacy and safety profiles comparable to daily treatment regimens.

In December 2024, Double Point Ventures (DPV), a U.S.-based venture capital firm, acquired Lumos Pharma for $38 million. Through this acquisition, Double Point Ventures seeks to strengthen its biopharmaceutical portfolio by incorporating Lumos Pharma’s expertise in developing therapies for rare diseases, particularly its lead candidate LUM-201, an oral growth hormone secretagogue currently in Phase 2 clinical trials for pediatric growth hormone deficiency. Lumos Pharma is a U.S.-based biotechnology company engaged in the development of treatments for Turner syndrome.

Major companies operating in the turner syndrome market are Pfizer Inc., Novartis AG, Eli Lilly and Company, Novo Nordisk, Merck KGaA, Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Genentech Inc., Ipsen Pharma, Ferring Pharmaceutical, BioMarin Pharmaceutical Inc., Ascendis Pharma, CRISPR Therapeutics AG, Alnylam Pharmaceuticals Inc., Sangamo Therapeutics Inc., Ultragenyx Pharmaceutical Inc., BridgeBio Pharma Inc., Travere Therapeutics Inc., REGENXBIO Inc., Avalo Therapeutics Inc., Taysha Gene Therapies Inc., Asklepion Therapeutics Inc.

North America was the largest region in the turner syndrome market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the turner syndrome market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the turner syndrome market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the turner syndrome market by increasing costs of imported growth hormone formulations, diagnostic genetic testing kits, specialty pharmaceuticals, and medical devices used in long-term disease management. Hospitals and specialty clinics in emerging economies are most affected due to reliance on imported branded therapies. These tariffs are increasing treatment costs and limiting therapy access. However, they are also encouraging domestic production of biosimilar hormones, local diagnostic testing capabilities, and stronger regional supply chains for rare disease treatments.

The turner syndrome market research report is one of a series of new reports that provides turner syndrome market statistics, including turner syndrome industry global market size, regional shares, competitors with a turner syndrome market share, detailed turner syndrome market segments, market trends and opportunities, and any further data you may need to thrive in the turner syndrome industry. This turner syndrome market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Turner syndrome is a genetic disorder affecting females that arises from the partial or complete absence of one X chromosome. This condition can cause a variety of developmental and medical issues, including short stature, delayed puberty, infertility, cardiovascular abnormalities, and certain learning challenges. Turner syndrome is usually diagnosed through karyotype analysis and managed with specialized medical care to address associated health complications.

The main types of Turner syndrome include classical Turner syndrome and mosaic Turner syndrome. Classical Turner syndrome is the most common form and is defined by the complete absence of one X chromosome in females. Treatment involves therapies such as growth hormone therapy, estrogen and progesterone replacement therapy, and others, with several drugs used for management, including Norditropin, oxandrolone, Humatrope, somatropin, Oxandrin, Genotropin, Nutropin, and Zomacton. These treatments are utilized by various end users, including hospitals, homecare settings, specialty clinics, surgical centers, and others.

The turner syndrome market consists of revenues earned by entities by providing services such as genetic counseling, diagnostic testing services, fertility and reproductive health support. The market value includes the value of related goods sold by the service provider or included within the service offering. The turner syndrome market also includes sales of genetic testing kits, cardiac monitoring devices and bone density supplements. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.